BACKGROUND: Ziconotide is a non-opioid drug indicated for management of severe chronic
pain in patients for whom intrathecal (IT) therapy is warranted and who are intolerant of or …

Objectives. The inhaled corticosteroid fluticasone propionate (fluticasone) and the long-acting
β 2 agonist formoterol fumarate (formoterol) have been combined in a single aerosol …

The purpose of this article is to document the discussions at the 2010 European Workshop
on Equivalence Determinations for Orally Inhaled Drugs for Local Action, cohosted by the …

Objectives This study aims to assess the safety and efficacy of long-term intrathecal (IT)
ziconotide infusion. Materials and Methods In this prospective study, 155 patients with severe …

… Tammy McIver and Sanjeeva Dissanayake were employees of the study … Dissanayake SB.
Safety of β2-agonists in asthma: linking mechanisms, meta-analyses … Sanjeeva Dissanayake …

… Dr Sanjeeva Dissanayake, Medicines and Healthcare products Regulatory Agency (MHRA),
Market Towers, 1 Nine Elms Lane, London SW8 5NQ, UK.Tel: +44 020 7084 3728Fax: +44 …

Background: A primary goal of asthma management is the reduction of exacerbation risk. We
assessed the occurrence of oral corticosteroid-requiring exacerbations (OCS exacerbations…

… Dr Dissanayake wrote the first draft of this manuscript. Both Dr Dissanayake and Dr
Suggett were involved in the analysis and interpretation of data and the decision to submit the …

Objective: To demonstrate the efficacy and safety of fluticasone propionate/formoterol fumarate
(flutiform ) in a pressurised metered-dose inhaler (pMDI) compared to two formulations of …

International asthma management guidelines recommend a long-acting β 2 -agonist (LABA)
as add-on therapy in patients whose asthma is not controlled by low-dose inhaled …